Welcome to our dedicated page for VISKASE HOLDINGS SEC filings (Ticker: ENZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enzon Pharmaceuticals, Inc. (ENZN) files a range of documents with the U.S. Securities and Exchange Commission that are central to understanding its role as a public company acquisition vehicle and its proposed merger with Viskase Companies, Inc. On this page, you can review Enzon’s Form 8-K current reports, which detail material events such as the execution of the Agreement and Plan of Merger, subsequent amendments to that agreement, and changes to its Section 382 Rights Agreement.
Merger-related 8-K filings describe the structure of the all-stock transaction in which Viskase will merge with and into a wholly owned Enzon subsidiary, the exchange ratios between Viskase common stock, Enzon common stock, and Enzon’s Series C Non-Convertible Redeemable Preferred Stock, and the anticipated post-merger ownership split, including the expectation that current Viskase stockholders will own 55% of the combined company following the amended merger terms. These filings also outline requirements such as a 1-for-100 reverse stock split of Enzon common stock and the role of Icahn Enterprises Holdings L.P. and its affiliates under a support agreement.
Other key filings relate to Enzon’s Section 382 Rights Agreement. Through multiple amendments reported on Form 8-K, Enzon has adjusted the Final Expiration Date of the rights issued under this agreement. The company notes that these amendments are intended to revise the expiration date while leaving the rest of the agreement unchanged, and that management believes the revised dates are in the best interests of stockholders.
Enzon has also stated that it intends to file a registration statement on Form S-4 in connection with the Viskase merger. That filing is expected to contain a consent solicitation statement and prospectus and to include financial information about the combined company. On this page, AI-powered tools can help summarize lengthy filings, highlight key transaction terms, and make it easier to understand complex documents such as merger agreements, rights agreements, and related exhibits.
Viskase Holdings, Inc. announced that its wholly owned subsidiary Viskase Companies, LLC entered into a Seventh Amendment to its Credit Agreement, extending the debt maturity date from August 13, 2026 to August 13, 2027.
The amendment increases the Applicable Rate by 1.0 percentage point on revolving loans, term loans and letters of credit, adjusts the definition of Consolidated EBITDA for certain restructuring and transaction costs, and permits asset dispositions at the Osceola Facility and Chicago Property. The amended facility continues to include customary covenants, is guaranteed by material restricted subsidiaries (other than Brazilian subsidiaries), and is secured by substantially all assets other than real property.
Viskase Holdings, Inc., formerly Enzon Pharmaceuticals, Inc., completed its merger with Viskase Companies, Inc. and subsequently changed its corporate name. Following this transaction, the Audit Committee appointed Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with unanimous Board ratification, subject to completion of client acceptance procedures.
Grant Thornton previously served as Viskase’s auditor before the merger. As a result of the change, EisnerAmper LLP, Enzon’s prior auditor, was dismissed. EisnerAmper’s reports on the company’s 2024 and 2025 financial statements were unqualified, and the company reports no disagreements or reportable events with EisnerAmper during that period. The company also states it did not consult Grant Thornton on accounting or auditing matters before the appointment.
Viskase Holdings, Inc. has promoted long-time finance executive Michael Blecic to Chief Financial Officer, effective April 10, 2026. Blecic, age 57, has worked at the company’s subsidiary since 1995 and has served as Vice President, Chief Accounting Officer and Treasurer since February 2013, roles he will retain.
The interim Chief Financial Officer engagement with Mackenzie Stender through Silverman Consulting, Inc. ended as of the same date. Viskase also appointed Joseph D. King as Executive Vice President while he continues as Senior Vice President, General Counsel and Secretary. Neither Blecic nor King will receive additional compensation beyond normal annual merit increases for these new titles.
Viskase Holdings, Inc. reported insider ownership changes tied to a merger and reverse stock split, not open-market trading. An entity affiliated with Carl C. Icahn disposed of 39,277 shares of preferred stock in a transaction to the issuer, exchanged for 5,658,396 shares of common stock in connection with the merger of the company and Viskase Companies, Inc.
Additional common shares were received in the merger and adjusted for a 1-for-100 reverse stock split effected on March 25, 2026. Following these transactions, entities associated with Icahn indirectly held 13,426,451 shares of common stock through American Entertainment Properties Corp, with Icahn and related entities disclaiming beneficial ownership beyond any pecuniary interest.
Carl C. Icahn and affiliated entities report owning 13,426,451 shares of Viskase Holdings, Inc. common stock, representing 93.7% of the company’s 14,331,713 outstanding shares as of March 26, 2026. This amended Schedule 13D reflects changes tied to Viskase’s merger with Viskase Companies, Inc.
On March 25, 2026, the Icahn group exchanged 39,277 shares of preferred stock for 5,658,396 Viskase common shares under an IEH Support Agreement. On March 26, 2026, they received a further 7,407,489 Viskase shares in exchange for 150,810,078 Viskase Companies, Inc. shares at the merger closing. Three Icahn-affiliated executives—Robert Flint, Colin Kwak, and Dustin DeMaria—joined Viskase’s board of directors in connection with the merger.
Viskase Holdings, Inc. filed an initial insider ownership report for company officer Joseph D. King
Viskase Holdings, Inc. director Kenneth Shea filed an initial ownership report on Form 3 for the company’s stock. The filing lists him as a director of Viskase but shows no reportable transactions or derivative positions and no share counts in this data excerpt.
Viskase Holdings, Inc. reported that executive Armando Herrera Jr. filed an initial Form 3 as an officer of the company. The filing lists no stock transactions and shows no reported derivative positions or holdings in the provided data. This is a routine disclosure of insider status required under SEC rules.
Viskase Holdings, Inc. director Robert Flint has filed an initial statement of beneficial ownership on Form 3. This filing identifies him as a director of the company but, based on the available data, does not report any stock purchases, sales, option exercises, gifts, or other transactions.
Viskase Holdings, Inc. director Dustin DeMaria submitted an initial statement of beneficial ownership as a Form 3 filing. The available data show no reported stock transactions and no derivative security positions in this filing, indicating it mainly serves as a baseline disclosure of his status as a director.